Free public records show Fujian Shengdi Pharmaceutical Co., Ltd. in 9 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Fujian Shengdi Pharmaceutical Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
30 active studies led by Fujian Shengdi Pharmaceutical Co., Ltd., of 66 in all
Source: ClinicalTrials.gov, Studies with Fujian Shengdi Pharmaceutical Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Fujian Shengdi Pharmaceutical Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Fujian Shengdi Pharmaceutical Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Fujian Shengdi Pharmaceutical Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Fujian Shengdi Pharmaceutical Co., Ltd. is in.
Stories on the topics Fujian Shengdi Pharmaceutical Co., Ltd. works in.
2.6 billion adults are overweight. GLP-1 medicines are changing weight care, while most supplements lack…
Read
Nearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year…
Read
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
ReadSearch all reports for Fujian Shengdi Pharmaceutical Co., Ltd. All companies